Brought to you by 
GlobeImmune closes $38.4mm Series B round
20 Jan 2006
Executive Summary
GlobeImmune (therapies for cancer and infectious diseases) raised $38.4mm in a two-part Series B preferred share financing. The first tranche in September 2005 brought in $34.3mm through lead investor Lilly Ventures and other new backers Medica Holdings, Adams Street Partners, Biogen Idec, Genentech, Partners HealthCare, and GC&H Investments participated along with returning shareholders HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners. The $4.1mm second close included investments from Pac-Link, CIDC, and Yasuda Enterprise Development.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GlobeImmune closes $38.4mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice